Tau transgenic mice as models for cerebrospinal fluid tau biomarkers

Journal of Alzheimer's Disease

Volumn 24, Issue SUPPL. 2, 2011, Pages 127-141

  Barten, Donna M ^a   Cadelina, Gregory W ^a   Hoque, Nina ^a   Decarr, Lynn B ^a   Guss, Valerie L ^a   Yang, Ling ^a   Sankaranarayanan, Sethu ^a   Wes, Paul D ^a   Flynn, Marianne E ^a   Meredith, Jere E ^a   Ahlijanian, Michael K ^a   Albright, Charles F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Alzheimer's disease; cerebrospinal fluid; ELISA; FTDP 17 protein; human; MAPT; mice; tau proteins; tauopathy; transgenic

Indexed keywords

DOXYCYCLINE; TAU PROTEIN;

AGE DISTRIBUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DOMAIN; PROTEIN STRUCTURE; TAUOPATHY; TRANSGENE; TRANSGENIC MOUSE;

EID: 79955646448     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-110161     Document Type: Article

References (48)

1. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
2. Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C (2005) Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet 21, 664-672. (Pubitemid 41608689)
3. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ (2010) Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45, 30-40.
4. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypo-thetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
6. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Tro-janowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
7. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cogni-tive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8, 619-627.
8. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286.
9. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E (2009) Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 25, 403-410.
10. Lin YT, Cheng JT, Yao YC, Juo, Lo YK, Lin CH, Ger LP, Lu PJ (2009) Increased total TAU but not amyloid-beta(42) in cere-brospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis 18, 907-918.
11. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D, Morris JC, Fagan AM, Holtzman DM, Goate AM (2010) SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6, pii: e 1001101.
12. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353-1358.
13. Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM (2009) Baseline CSF p-tau levels inde-pendently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73, 935-940.
14. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
15. van Rossum IA, Vos S, Handels R, Visser PJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 20, 881-891.
16. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003) Cerebral glucose metabolism, cerebro-spinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apo-lipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 338, 159-163. (Pubitemid 36140161)
17. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER (2006) Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 10, 399-406.
18. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
19. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
20. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Nor-ton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snow-den J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunc-tion. Neuron 39, 409-421. (Pubitemid 36937044)
22. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingels-son M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. (Pubitemid 40994688)
23. Tucker KL, Meyer M, Barde YA (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci 4, 29-37.
24. Congdon EE, Figueroa YH, Wang L, Toneva G, Chang E, Kuret J, Conrad C, Duff KE (2009) Inhibition of tau poly-merization with a cyanine dye in two distinct model systems. J Biol Chem 284, 20830-20839.
25. van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, Gre-gory GC, Halliday GM, Gotz J, Kril JJ, Ittner LM (2009) Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm 116, 1243-1251.
26. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
27. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57, 721-729. (Pubitemid 40628861)
28. Cassar SC, Tovcimak AE, Rustay NR, Ellis TA, Hooker BA, Witte DG, Li J, Buck WR, Scharf D, Muller U, Jeromin A, Wang KK, Waring JF (2010) Comparing levels of biochem-ical markers in CSF from cannulated and non-cannulated rats. J Neurosci Methods 192, 249-253.
29. Zilka N, Korenova M, Kovacech B, Iqbal K, Novak M (2010) CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol 119, 679-687.
30. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006) CSF phosphorylated tau protein corre-lates with neocortical neurofibrillary pathology in Alzhei-mer's disease. Brain 129, 3035-3041. (Pubitemid 44684523)
31. Tolboom N, Koedam EL, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BN (2010) Dementia mimicking Alzheimer's disease owing to a tau mutation: CSF and PET findings. Alzheimer Dis Assoc Disord 24, 303-307.
32. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M, Ishizu H, Kashihara K, Yamamoto M, Tsuchiya-Ikemoto K, Morimatsu M, Takashima H, Nakagawa M, Kurokawa K, Maruyama H, Kaseda Y, Nakamura S, Hasegawa K, Oono H, Hikasa C, Ikeda K, Yamagata K, Wakutani Y, Takeshima T, Nakashima K (2001) Diagnostic significance oftauprotein in cerebrospinal fluid from patients with corticobasal degen-eration or progressive supranuclear palsy. J Neurol Sci 183, 95-98. (Pubitemid 32141077)
33. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Tro-janowski J, Lee VM, Grossman M (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology70, 1827-1835. (Pubitemid 351653951)
34. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hur-tig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Biomarker discovery for Alzheimer's disease, fron-totemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 120, 385-399.
35. Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, van Swieten JC (2003) Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 60, 1209-1213. (Pubitemid 37099625)
36. Bartosik-Psujek H, Stelmasiak Z (2006) The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J Neural Transm 113, 339-345. (Pubitemid 43201100)
37. Levine TD, Bowser R, Hank N, Saperstein D (2010) A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler 11, 514-519.
38. Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nell-gard B (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600-1604. (Pubitemid 44747930)
39. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vander-stichele H, Vanmechelen E, Blennow K (2001) Transient increase in total tau but not phospho-tau in human cere-brospinal fluid after acute stroke. Neurosci Lett 297, 187-190. (Pubitemid 32011305)
40. Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF (2010) Inter-neuronal transfer of human tau between Lamprey central neu-rons in situ. J Alzheimers Dis 19, 647-664.
41. Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D (1997) The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived frag-ments. JNeurochem 68, 430-433. (Pubitemid 26427338)
42. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70, 624-630. (Pubitemid 32397998)
43. Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, Bonuccelli U, Grassi M, Perani D, Calabresi P, Di Luca M, Padovani A (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71, 1796-1803.
44. Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Hoglund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, Blennow K, Gobom J (2008) Characterization oftau in cerebrospinal fluid using mass spec-trometry. J Proteome Res 7, 2114-2120.
45. Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL (2004) Proteins released from degenerating neu-rons are surrogate markers for acute brain damage. Neurobiol Dis 16, 311-320. (Pubitemid 38757313)
46. Wang Y, Garg S, Mandelkow EM, Mandelkow E (2010) Pro-teolytic processing of tau. Biochem Soc Trans 38, 955-961.
47. Bulat N, Widmann C (2009) Caspase substrates and neurode-generative diseases. Brain Res Bull 80, 251-267.
48. Dolan PJ, Johnson GV (2010) A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem 285, 21978-21987.